Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

What was studied

This was a secondary analysis of the TRIANGLE trial. It was in younger adults with untreated mantle cell lymphoma. The arms used ibrutinib-containing care, with or without stem cell transplant. It asked if rituximab maintenance, RM, helps. It covered people who responded to first care or transplant. There were 274 and 237 in the arms.

What they found

RM was linked to longer progression-free survival in both ibrutinib arms. Overall survival showed trends toward longer survival with RM. RM groups had a higher risk of grade 3 to 5 infection toxicity.

What it means for patients

The team says the data support adding RM to BTK inhibitor care. This is for younger, untreated people with mantle cell lymphoma. The aim is longer remission.

Why it is not certain yet

RM was not randomized. It was given as local practice allowed. Groups were compared with weighting methods. Overall survival gaps were only trends. This text uses the abstract and nothing else. Not every fact is in the abstract. Some of the work is not described there. Full data tables are not shown.

Source

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.